Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)
- PMID: 35934601
- DOI: 10.1016/j.eururo.2022.07.011
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)
Abstract
Context: The prognostic importance of local failure after definitive radiotherapy (RT) in National Comprehensive Cancer Network intermediate- and high-risk prostate cancer (PCa) patients remains unclear.
Objective: To evaluate the prognostic impact of local failure and the kinetics of distant metastasis following RT.
Evidence acquisition: A pooled analysis was performed on individual patient data of 12 533 PCa (6288 high-risk and 6245 intermediate-risk) patients enrolled in 18 randomized trials (conducted between 1985 and 2015) within the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium. Multivariable Cox proportional hazard (PH) models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), distant metastasis-free survival (DMFS), and local failure as a time-dependent covariate. Markov PH models were developed to evaluate the impact of specific transition states.
Evidence synthesis: The median follow-up was 11 yr. There were 795 (13%) local failure events and 1288 (21%) distant metastases for high-risk patients and 449 (7.2%) and 451 (7.2%) for intermediate-risk patients, respectively. For both groups, 81% of distant metastases developed from a clinically relapse-free state (cRF state). Local failure was significantly associated with OS (hazard ratio [HR] 1.17, 95% confidence interval [CI] 1.06-1.30), PCSS (HR 2.02, 95% CI 1.75-2.33), and DMFS (HR 1.94, 95% CI 1.75-2.15, p < 0.01 for all) in high-risk patients. Local failure was also significantly associated with DMFS (HR 1.57, 95% CI 1.36-1.81) but not with OS in intermediate-risk patients. Patients without local failure had a significantly lower HR of transitioning to a PCa-specific death state than those who had local failure (HR 0.32, 95% CI 0.21-0.50, p < 0.001). At later time points, more distant metastases emerged after a local failure event for both groups.
Conclusions: Local failure is an independent prognosticator of OS, PCSS, and DMFS in high-risk and of DMFS in intermediate-risk PCa. Distant metastasis predominantly developed from the cRF state, underscoring the importance of addressing occult microscopic disease. However a "second wave" of distant metastases occurs subsequent to local failure events, and optimization of local control may reduce the risk of distant metastasis.
Patient summary: Among men receiving definitive radiation therapy for high- and intermediate-risk prostate cancer, about 10% experience local recurrence, and they are at significantly increased risks of further disease progression. About 80% of patients who develop distant metastasis do not have a detectable local recurrence preceding it.
Keywords: Distant metastasis; Local control; Local failure; Pooled analysis; Prostate cancer; Radiation therapy.
Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
Comment in
-
The Deep Blue of Prostate Cancer Metastasis Evolution: The LEVIATHAN Pooled Analysis.Eur Urol. 2022 Nov;82(5):499-500. doi: 10.1016/j.eururo.2022.08.006. Epub 2022 Aug 20. Eur Urol. 2022. PMID: 35995643 No abstract available.
Similar articles
-
Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.Eur Urol. 2020 Feb;77(2):201-208. doi: 10.1016/j.eururo.2019.10.008. Epub 2019 Nov 10. Eur Urol. 2020. PMID: 31718822 Free PMC article.
-
Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.Eur Urol. 2020 Jan;77(1):3-10. doi: 10.1016/j.eururo.2019.03.022. Epub 2019 Apr 13. Eur Urol. 2020. PMID: 30992160 Free PMC article.
-
Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.Prostate. 2018 Jun;78(8):623-630. doi: 10.1002/pros.23507. Epub 2018 Mar 9. Prostate. 2018. PMID: 29520847
-
Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.JAMA Oncol. 2019 Jan 1;5(1):91-96. doi: 10.1001/jamaoncol.2018.3732. JAMA Oncol. 2019. PMID: 30326032 Free PMC article.
-
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.Eur Urol. 2020 May;77(5):614-627. doi: 10.1016/j.eururo.2020.01.033. Epub 2020 Mar 4. Eur Urol. 2020. PMID: 32146018
Cited by
-
Timing and Patterns of Potentially Salvageable Recurrences Following Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer Assessed by Preferential Amino Acid Uptake.Cureus. 2025 Jan 25;17(1):e77964. doi: 10.7759/cureus.77964. eCollection 2025 Jan. Cureus. 2025. PMID: 39996202 Free PMC article.
-
Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT).BMJ Open. 2022 Nov 8;12(11):e068580. doi: 10.1136/bmjopen-2022-068580. BMJ Open. 2022. PMID: 36351720 Free PMC article.
-
The Proteogenomics of Prostate Cancer Radioresistance.Cancer Res Commun. 2024 Sep 1;4(9):2463-2479. doi: 10.1158/2767-9764.CRC-24-0292. Cancer Res Commun. 2024. PMID: 39166898 Free PMC article.
-
How To Manage T3b Prostate Cancer in the Contemporary Era: The Benefits of Surgery.Eur Urol Open Sci. 2023 May 29;53:55-57. doi: 10.1016/j.euros.2023.05.004. eCollection 2023 Jul. Eur Urol Open Sci. 2023. PMID: 37287634 Free PMC article. No abstract available.
-
Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.J Clin Oncol. 2023 Nov 10;41(32):5005-5014. doi: 10.1200/JCO.23.00617. Epub 2023 Aug 28. J Clin Oncol. 2023. PMID: 37639648 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical